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654Objective: To discover the effects of the lowest hematocrit during cardiopulmonary bypass on end-organ func-
tion and mortality in patients who did not receive red blood cell transfusion and to identify predictors of nadir
hematocrit.
Methods: From November 1, 2004, to October 1, 2009, 7957 patients underwent cardiac surgery supported by
cardiopulmonary bypass and were not transfused. The relationship between nadir hematocrit and morbidity,
markers of end-organ function, and survival was studied using generalized propensity score analysis. Factors
associated with nadir hematocrit were identified by linear regression.
Results:Median nadir hematocrit was 30% (25th to 75th percentile, 27%–33%). Lower nadir hematocrit was
associated with higher maximum intraoperative lactic acid (intrasubject correlation,0.44). After risk adjust-
ment, nadir hematocrit was associated with worse renal function (lower estimated glomerular filtration rate;
P ¼ .012), more myocardial injury (higher troponin level; P ¼ .004), longer postoperative ventilator support
(P<.001), longer hospital stay (P<.001), and higher mortality (P ¼ .042). Female gender, older age, lower
body mass index, higher New York Heart Association class, and combined valve procedure and coronary artery
bypass were associated with lower nadir hematocrit; however, the strongest correlate was preoperative
hematocrit (correlation coefficient, 0.74).
Conclusions: Although red blood cell transfusion has associated morbidity risk, there must be a tradeoff be-
tween adverse effects of low hematocrit during cardiac surgery and those of transfusion. The strong association
of nadir hematocrit with preoperative hematocrit suggests the need for investigation and optimization before
elective cardiac surgery. (J Thorac Cardiovasc Surg 2012;144:654-62)Supplemental material is available online.More than one half million patients yearly undergo cardiac
surgery with the support of cardiopulmonary bypass (CPB).
More than half of these patients receive homologous blood
transfusions.1 Anemia is considered a major risk of these
procedures and is primarily related to hemodilution from
the CPB priming solutions and intravenous crystalloids,
surgical bleeding, and coagulopathy. Blood conservation
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The Journal of Thoracic and Cardiovascular Surgthe quality of care, optimize resource usage, lower costs,
and achieve better outcomes. Integral to these programs is
tolerance of anemia; however, anemia can impair tissue per-
fusion, particularly in patients with cardiovascular disease,
and result in end-organ injury. To date, a safe lower bound-
ary for hematocrit (Hct) has not been determined.
Several studies have associated nadir Hct and red blood
cell (RBC) transfusion with adverse clinical outcomes.2-14
However, the ability to discern whether adverse effects
are attributable to nadir Hct is confounded by
concomitant RBC transfusion, which itself introduces
adverse effects. Thus, our objectives were to clarify the
relationship between nadir Hct and end-organ function
and mortality in cardiac surgical patients who were not
transfused and to identify factors associated with nadir Hct.METHODS
Patients
From November 1, 2004, to October 1, 2009, 15,279 consecutive pa-
tients underwent cardiac surgery requiring CPB at the Cleveland Clinic.
Of these, 7957 did not receive an RBC transfusion during or after surgery.
The baseline demographics and perioperative variables were retrieved from
the Cardiovascular Information Registry, a prospective database updated
concurrently with patient care (Table 1). The institutional review board ap-
proved the use of data from this registry for research, with patient consent
waived.ery c September 2012
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
eGFR ¼ estimated glomerular filtration rate
Hct ¼ hematocrit
RBC ¼ red blood cell
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MEndpoints
The endpoints were hospital morbidity and mortality, markers of end-
organ function, resource usage, and long-term survival. Hospital morbid-
ities (perioperative myocardial infarction, respiratory failure, sepsis, renal
failure, and neurologic complications) were recorded prospectively accord-
ing to definitions from the Society of Thoracic Surgeons National Adult
Cardiac Database (available from: http://www.ctsnet.org/file/rptData
Specifications252_1_ForVendorsPGS.pdf). Intensive care unit and postop-
erative lengths of stay were used as surrogates for resource use, as was the
number of ventilator hours required postoperatively. Serial values of spe-
cific markers of end-organ function included troponin, estimated glomeru-
lar filtration rate (eGFR), and lactic acid.
Cardiovascular Information Registry follow-up data supplemented with
Social Security Death Master File information were used to determine the
vital status. The median follow-up was 2.6 years (interquartile range,
1.3–3.9 years). A total of 20,677 patient-years of follow-up were available
for analysis; 25% of patients were followedmore than 4 years and 10% for
more than 4.7 years.
Statistical Analysis
Patient demographics, perioperative risk factors, and postoperative out-
comes were summarized using the median and interquartile range (contin-
uous variables) or frequency counts and percentages (categorical
variables). Missing values were sporadic, without strong mechanism for in-
formative missingness. They were imputed with the mean of available data
(except for the categorical variable, NewYork Heart Association functional
class, for which we created a separate category for its missing value). Of
7957 patients, 6928 (87.1%) had 1 to 5 CPB Hct values. In general, an ar-
terial blood sample was obtained every 30 minutes during CPB for mea-
surement of Hct and lactate. Hct was not measured during CPB in 56
patients (0.7%); we used their lowest intraoperative Hct as a surrogate
for nadir Hct during CPB.
The univariate relationship between nadir Hct and outcomes was ex-
plored using penalized spline models. The adjusted effect of nadir Hct
on outcomes, given confounders, was analyzed using a generalized propen-
sity score analysis.15 Similar to the traditional 2-group propensity score
analysis,16 generalized propensity score analysis offers a method of strati-
fying patients such that within each stratum, nadir Hct and confounders ap-
pear to be unrelated. Thus, the association between nadir Hct and outcomes
is unconfounded within each stratum, and aggregated result across all strata
forms an estimator of the independent effect of nadir Hct on outcomes
(see Appendix E1).
Intraoperative Hct and lactic acid were measured simultaneously during
surgery. We calculated their within-subject correlation and formed an aver-
age correlation coefficient. Its confidence interval was calculated using the
bootstrap method.
We used a linear regression model with stepwise variable selection to
identify preoperative risk factors associated with nadir Hct. Spline terms
of continuous predictors were used to check the linearity assumption.
The sandwich variance estimator was used to guard against possible hetero-
geneity or non-normality in the residual distribution.
All P values are 2-sided. Statistical analyses were performed with SAS,
version 9.1 (SAS Institute, Cary, NC) and R 2.12.2 (R Foundation for Sta-
tistical Computing, Vienna, Austria).17The Journal of Thoracic and CaRESULTS
Unadjusted Nadir Hct and End-Organ Dysfunction
Nadir Hct ranged from 15% to 46% (median, 30%).
Most often, the Hct level decreased from baseline shortly
after beginning CPB and gradually recovered as the opera-
tion proceeded (Figure E1).
Theunadjusted association betweennadirHct and selected
outcomes is shown inFigure 1.NadirHctwas associatedwith
lower eGFR and higher troponin levels, suggesting renal and
myocardial injury were more likely with a lower nadir Hct.
Nadir Hct had no significant association with intensive care
unit length of stay. An inverse relationship was seen between
nadirHct and the duration ofmechanical ventilation and hos-
pital length of stay. On average, patients with a nadir Hct of
20%were discharged 2.7 days later than patientswith a nadir
Hct of 35%. Three-year survival decreased from 98% to
85% as nadir Hct decreased from 35% to 20%.
Risk-Adjusted Nadir Hct and End-Organ
Dysfunction
The risk-adjusted association of nadir Hct with each out-
come is listed in Table 2, and Figure 2 illustrates those re-
lationships. In Table 2, the associations are quantified as
the regression coefficients of nadir Hct in the regression
of each outcome, stratifying on the generalized propensity
score. Nadir Hct was associated with higher mortality,
more troponin release, lower eGFR, longer duration of me-
chanical ventilation, and longer length of hospital stay.
Three-year adjusted survival decreased from 97% to 93%
as nadir Hct decreased from 35% to 20%.
Pearson’s correlation was0.12 (95% confidence inter-
val,0.16 to0.076) between the maximum intraoperative
lactic acid level and nadir Hct, as determined from 2156
patients with available lactic acid data. A within-subject
correlation analysis of 1893 patients, each with at least 5
pairs of intraoperative Hct and lactic acid measurements,
showed that the average within-subject correlation coeffi-
cient between intraoperative Hct and lactic acid level was
0.44 (95% confidence interval,0.45 to0.42). Both re-
sults suggest impaired tissue perfusion at lower Hct values.
Sensitivity analyses using multivariate models were per-
formed to confirm the results of the generalized propensity
score analysis. We built regression models for the key out-
comes using the variables listed in Table 1. The sensitivity
analysis produced consistent results with the generalized
propensity score analysis. Nadir Hct was associated with
lower eGFR, greater troponin release, longer postoperative
ventilation time, longer hospital length of stay, lower sur-
vival, and an increase in late mortality (see Appendix E2
and Tables E1 to E7).
Risk Factors for Nadir Hct
The factors associated with lower nadir Hct included
lower preoperative Hct, older age, female gender, lowerrdiovascular Surgery c Volume 144, Number 3 655
TABLE 1. Patient characteristics (n ¼ 7957)
Characteristic
Total patients
(n)*
Median or
count
Demographics
Age (y) 7957 61 (51–69)
Gender 7957
Men 5949 (75)
Women 2008 (25)
White race 7727 7219 (93)
Year of surgery 7957
2004 320 (4)
2005 1669 (21)
2006 1596 (20)
2007 1487 (19)
2008 1587 (20)
2009 1298 (16)
Preoperative clinical and laboratory data
BMI (kg/m2) 7820 28.1 (25.1–32.0)
Hct (%) 7957 42 (39–46)
BUN (mg/dL) 7951 17 (14–21)
eGFR (mL/min/1.73 m2) 7721 75 (64–87)
Bilirubin (mg/dL) 7874 0.6 (0.4–0.8)
Disease severity
NYHA functional class 6867
1 2066 (30)
2 3355 (49)
3 1336 (19)
4 110 (1.6)
Emergency operation 7955
Yes 27 (0.3)
No 7928 (99.7)
IABP 7957
Yes 26 (0.3)
No 7931 (99.7)
Cardiac comorbidity
Coronary artery disease 6980
LMT (>70%)
Yes 344 (4.9)
No 6636 (95.1)
RCA (>70%)
Yes 7010 1856 (26)
No 5154 (74)
EF (%) 7722 55 (50–60)
Preoperative AF
Yes 7713 748 (9.7)
No 6965 (90.3)
History of heart failure
Yes 7957 1400 (18)
No 6557 (82)
Previous MI
Yes 7957 1582 (20)
No 6375 (80)
History of cardiogenic shock
Yes 7957 26 (0.3)
No 7931 (99.7)
(Continued)
TABLE 1. Continued
Characteristic
Total patients
(n)*
Median or
count
History of peripheral arterial disease
Yes 7957 1980 (25)
No 5977 (75)
Previous cardiac operation
Yes 7957 1046 (13)
No 6911 (87)
Previous cardiac operations
1 7957 6919 (87)
2 1038 (13)
History of hypertension
Yes 7957 5033 (63)
No 2924 (37)
Noncardiac comorbidity
Previous stroke
Yes 7957 421 (5.3)
No 7536 (94.7)
History of carotid disease
Yes 7957 1818 (23)
No 6139 (77)
History of smoking
Yes 7950 3998 (50)
No 3952 (50)
History of COPD
Yes 7957 793 (10)
No 7164 (90)
History of NIDDM
Yes 7893 1047 (13)
No 6846 (87)
History of IDDM
Yes 7893 429 (5.4)
No 7464 (94.6)
History of renal disease
Yes 7957 128 (1.6)
No 7829 (98.4)
Operative factors
Nadir Hct (%) 7957 29.7 (26.7–32.6)
Type of operation 7957
Isolated CABG 1610 (20)
Isolated valve 2695 (34)
CABG and valve combined 882 (11)
Other 2770 (35)
Internal thoracic artery grafts
Yes 7957 2358 (30)
No 5599 (70)
CPB time (min) 7957 86 (66–109)
Aortic clamp time (min) 7957 66 (51–85)
Data presented as median (interquartile range [25th–75th percentile]) for continuous
variables and counts (percentages) for categorical variables. BMI, Body mass index;
Hct, hematocrit; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration
rate; NYHA, New York Heart Association; IABP, intra-aortic balloon pump; LMT,
left main trunk; RCA, right coronary artery; EF, ejection fraction; AF, atrial fibrilla-
tion; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease;
NIDDM, non–insulin-dependent diabetes mellitus; IDDM, insulin-dependent diabe-
tes mellitus; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass.
*Patients with available data.
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FIGURE 1. Unadjusted patient outcomes associated with nadir hematocrit (Hct). Relationship represented by black solid line. Gray area indicates 95%
point-wise confidence band. eGFR, Estimated glomerular filtration rate; ICU, intensive care unit.
Loor et al Perioperative Management
P
Mbody mass index, peripheral arterial disease, renal disease,
procedure complexity, and longer CPB duration (Table 3).
The strongest correlatewas preoperativeHct, with a Pearson
correlation coefficient of 0.74. With all other variables
fixed, older age, lower body mass index, higher New York
Heart Association functional classification, and longer du-
ration of CPB were associated with a decrease in predicted
nadir Hct (Figure 3).
DISCUSSION
A restrictive RBC transfusion strategy is integral to cur-
rent blood management programs for cardiac surgery. PartThe Journal of Thoracic and Caof this strategy is a tolerance for perioperative anemia, but
without the ability to predict whether a given level of ane-
mia is safe. In our study, nadir Hct was associated with
more end-organ dysfunction and mortality in a cohort of
nontransfused cardiac surgical patients.
Other studies have explored the influence of anemia on
surgical outcomes; however, many of these studies did not
control for the concomitant influence of RBC transfusion.
Moreover, the effects of preoperative anemia are difficult
to separate from the effects of anemia occurring during
CPB. Approximately 25% to 30% of patients undergoing
cardiac surgery are anemic before the procedure, and thisrdiovascular Surgery c Volume 144, Number 3 657
TABLE 2. Risk-adjusted relationship between nadir hematocrit and
morbidity outcomes
Outcomes
Effect*
(P value)
Lower nadir Hct
associated with
24-h mean troponiny 0.12 (.0042) Higher postoperative
troponin
Lowest eGFR (mL/min/1.73 m2)
within 72 h
2.4 (.012) Worse renal function
Postoperative ventilator support 1.2 (<.001) Greater need for
ventilation
Ventilation duration (h),
if neededy
0.1 (.0057) Longer ventilation
time
Postoperative ICU stay (h)y 0.047 (.062) Not significant
Postoperative hospital
length of stayy
0.083 (<.001) Longer postoperative
stay
Interval to all-cause death 0.46 (.042) Higher risk of death
Hct, Hematocrit; eGFR, estimated glomerular filtration rate; ICU, intensive care unit.
*Only in these analyses, Hct is expressed as change/10-unit increase in percentage of
Hct; for troponin, eGFR, ventilation duration, and ICU and hospital length of stay,
linear regression analysis was used, and the effect is the mean change; for ventilation
support, logistic regression analysis was used, and the effect is the log odds ratio; for
survival, the Cox model was used, and the effect is the log hazard ratio. yNatural log-
arithmic transformation.
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Mis a recognized risk factor for increased morbidity and
mortality.18-20
Lower nadir Hct during CPB has been associated with in-
creased in-hospital and long-term mortality.6,7 A recent
study investigated the influence of nadir Hct on mortality
in a group of nontransfused patients undergoing isolated
coronary artery bypass grafting.3 The investigators found
an increase in major morbidity related to nadir Hct, but
no effect on survival. Two small randomized trials failed
to demonstrate a difference in operative, in-hospital, or
1-year survival for patients with low Hct during CPB.21,22
To investigate the relationship between anemia and poor
outcomes, we examined laboratory markers for end-organ
function with varying Hct levels. Swaminathan and col-
leagues2 showed that nadir Hct during CPB was associated
with a higher peak fractional change in creatinine and that
RBC transfusion further exacerbated the effects of low na-
dir Hct on renal function. Others have reported the suscep-
tibility of renal function to low nadir Hct, as reflected by
increased creatinine values and renal failure.5 We discov-
ered a significant interaction between nadir Hct and
eGFR. Patients progressed along a spectrum of mild renal
dysfunction as nadir Hct decreased from 30% to 20%.
This is a subtle, but important, finding. Previous studies
have shown that even mild degrees of renal dysfunction
can influence adverse outcomes among patients undergoing
cardiac surgery.23-25
Patients with a low nadir Hct have a greater prevalence of
postoperative myocardial infarction, cardiac arrest,6 intra-
aortic balloon pump use, and return to CPB.6,7 We did not
find an association between nadir Hct and Society
of Thoracic Surgeons–defined postoperative myocardial658 The Journal of Thoracic and Cardiovascular Surginfarction. However, we did note a relationship between
nadir Hct and the release of troponin. This subclinical
myocardial injury can be explained by a low nadir Hct in
the cardioplegia solution, which derives its Hct from
systemic circulation. The nadir Hct is often reached
shortly after the initiation of CPB and before the period of
protected ischemic arrest, which might explain this
increase in troponin. Although the implications of this
troponin release are unclear, it has been shown to be
a sensitive marker for perioperative myocardial infarction
and postoperative heart failure.26,27
The increased hospital length of stay associated with
lower nadir Hct might be related to fatigue-induced lack
of mobility in the immediate postoperative period. A recent
study reported that postoperative cardiac surgery patients
admitted to rehabilitation with hemoglobin values less
than 10 g/dL had significantly worse performance on the
6-minute walk test than patients with higher hemoglobin
values.28
Study Limitations
This was a prospective cohort investigation in which un-
measured variables could have biased the results from the
generalized propensity score analysis and regression
models. However, we improved on previous studies by in-
corporating a larger number of confounders into our model,
including preoperative anemia. Patients in the present in-
vestigation were lower risk than patients who received
blood transfusions, as previously demonstrated by our
group.10,11 Nadir Hct was analyzed as a continuous
variable, and we found no threshold below which the
morbidity sharply increased to suggest a sharp cutoff.
Furthermore, our analysis showed that the effect of nadir
Hct was different for individual organ systems and was
affected by the patients’ unique comorbidities. Thus, we
cannot recommend a subject- or morbidity-specific transfu-
sion trigger.
Clinical Implications
We identified several risk factors for low nadir Hct on
CPB that could guide patient selection and preoperative
management. Preoperative anemia should be investigated
for potentially reversible causes, and, if possible, surgery
should be delayed until Hct improves. The observation
that women had a lower preoperative Hct was consistent
with previous work from our group.29 Iron supplements
and short-term therapy with erythropoietin are possible in-
terventions. A number of intraoperative strategies can ame-
liorate reductions in Hct associated with surgery requiring
CPB. Retrograde autologous priming and smaller bypass
circuits are encouraged in patients with a low body mass in-
dex and low preoperative Hct. Many of these blood conser-
vation strategies have been implemented at our institution
during the past decade. These strategies did not confoundery c September 2012
FIGURE 2. Adjusted relationship between nadir hematocrit (Hct) and outcomes from generalized propensity score analysis. Gray lines indicate the re-
lationship within each patient strata defined by the generalized propensity score. Fifty strata were used, representing a spectrum of risk levels (except
for all-cause death, for which we combined 50 strata into 5 to estimate the baseline survival probability accurately). Solid line indicates average across
all strata. For comparison purposes, the dashed lines represent the same model between outcomes and nadir Hct without stratification. eGFR, Estimated
glomerular filtration rate; ICU, intensive care unit.
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Mour ability to examine the effect of nadir Hct on outcomes;
rather, they reduced the overall level of anemia experi-
enced by patient population. The relationship between
New York Heart Association functional class and nadir
Hct was most likely due to the patients’ excess free water
coupled with the CPB priming solution. These patients
should undergo diuresis before surgery to help avoid lower
nadir Hct.The Journal of Thoracic and CaFuture studies should address factors that can help define
subgroups of patients with severe intraoperative anemia
who would benefit from RBC transfusions. The risks of tol-
erating a lower Hct must be weighed against the risks of in-
terventions used to increase it, such as RBC transfusion. To
date, evidence has suggested that patients do worse when
given RBC products during cardiac surgery. Specifically,
for reasons that are not entirely understood, patients whordiovascular Surgery c Volume 144, Number 3 659
TABLE 3. Factors associated with lower nadir hematocrit
Factor
Regression
Coefficient* 95% CI
P
value
Demographics
Older age (per 5-y increase) 0.16 0.18,0.13 <.001
Lower BMI (per 5-kg/m2
decrease)
0.51 0.46, 0.56 <.001
Gender
Men 2.6 2.4, 2.7 <.001
Women 0 — —
Race (white) 0.56 0.33, 0.78 <.001
Year of surgery
2004 0 — —
2005 0.25 0.063, 0.56 .1
2006 0.48 0.16, 0.80 .003
2007 0.63 0.31, 0.94 <.001
2008 0.35 0.033, 0.67 .03
2009 0.069 0.39, 0.25 .7
Preoperative clinical and
laboratory data
Lower Hct (%) 0.55 0.54, 0.57 <.001
Lower bilirubin (mg/dL;
log scale)
0.37 0.25, 0.49 <.001
Disease severity
NYHA functional class
1 0 — —
2 0.18 0.32,0.04 .01
3 0.24 0.42,0.06 .009
4 0.11 0.63, 0.42 .7
IABP 1.2 2.3,0.13 .03
Cardiac comorbidity
Coronary artery disease
LMT (>70%) 0.48 0.76,0.19 .001
RCA (>70%) 0.31 0.48,0.13 <.001
Preoperative AF 0.54 0.32, 0.75 <.001
Previous cardiac operation 0.26 0.4,0.12 <.001
History of peripheral artery
disease
0.48 0.83,0.12 .009
Higher ejection fraction
(per 10% increase)
0.058 0.12, 0.0011 .054
Noncardiac comorbidity
History of carotid disease 0.44 0.064, 0.81 .02
History of renal disease 0.47 0.9,0.045 .03
Operative factors
Operation type
Isolated CABG 0.14 0.38, 0.11 .3
Isolated valve 0.29 0.15, 0.44 <.001
CABG and valve
combined
0.5 0.72,0.27 <.001
Other 0 — —
(Continued)
TABLE 3. Continued
Factor
Regression
Coefficient* 95% CI
P
value
Internal thoracic artery
graft
0.33 0.53,0.12 .002
Longer CPB time (h) 0.27 0.46,0.082 .005
Longer aortic clamp time
(h)
0.22 0.45, 0.0094 .06
The intercept of this model is 4.1 (95% CI, 3.2, 5.0). CI, Confidence interval; BMI,
body mass index; Hct, hematocrit; NYHA, New York Heart Association; IABP,
intra-aortic balloon pump; LMT, left main trunk; RCA, right coronary artery; AF, atrial
fibrillation; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass.
*The regression coefficient quantifies the increase in nadir Hct (%) for each unit in-
crease of the corresponding covariate (or the presence of the condition).
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Mreceive an RBC transfusion during cardiac surgery have an
incremental decrease in long-term survival proportionate to
the number of units received.11 Several large-scale observa-
tional studies have demonstrated an association between
RBC transfusion and increased morbidity after cardiac
surgery.9-11,13,14,30,31660 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
Nadir Hct is associated with more end-organ dysfunction
and increased resource usage and mortality. Preoperative
anemia is the most significant risk factor for low nadir
Hct. Identification and treatment of preoperative anemia
might eliminate the risk associated with both anemia and
RBC transfusion. Once perioperative anemia has occurred,
it is unclear whether tolerating the anemia would be riskier
than treating it with an RBC transfusion.References
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APPENDIX E1. TECHNICAL DETAILS ON
GENERALIZED PROPENSITY SCORE ANALYSIS
The analysis was started by developing a generalized pro-
pensity function for nadir hematocrit (Hct). In theory, this
is defined for each subject as the cumulative distribution
function of the conditional distribution of nadir Hct, given
all the confounders in Table 1. In the present investigation,
we found that a linear regression model with homogeneous
residual variance approximated the data well. In such situ-
ations, the generalized propensity function can be simpli-
fied as a generalized propensity score, which is the
predicted mean of nadir Hct from that linear regression.
The theory reported by Imai and van DykE1 shows that,
conditional on the generalized propensity score, nadir Hct
and all confounders were independent. Therefore, we can
use an approach similar to that of Rosenbaum and RubinE2
and stratify the subjects into a number of strata such that
subjects within each stratum have similar generalized pro-
pensity scores. For the present report, we used 50 strata.
The validity of the generalized propensity score analysis
can be checked by balance diagnosis. If the generalized
propensity score is calculated correctly, and the stratifica-
tion is adequate, we would expect that nadir Hct and con-
founders would be approximately independent within
each stratum. We used a balance-check procedure similar
to that reported by Rosenbaum and RubinE2 for 2-group
propensity score analysis. First, perform a 1-way analysis
of variance with a confounder (eg, age) as the dependent
variable and nadir Hct as the covariate. Second, perform
a 2-way analysis of variance with the strata indicator as
the second covariate. Finally, compare the F-statistic of
nadir Hct before and after adding the strata indicator. If
the generalized propensity score is calculated correctly
and the stratification is good, the F-statistic should be re-
duced to near 0 after stratification. We can define a thresh-
old by the upper tail (0.05 quartile) of the F-distribution
with the same degrees of freedom as the F-statistic, and
the F-statistic should be within the threshold with 95%
probability after stratification. The analysis of the associa-
tion between nadir Hct and outcomes proceeded by a strat-
ified regression model of each outcome on nadir Hct, with
no need to adjust for the large number of confounders in the
model. Linear regression was used for continuous out-
comes, logistic regression for binary outcomes, and strati-
fied Cox regression for time-to-event outcomes.
APPENDIX E2. SENSITIVITYANALYSIS
Multivariate regression models were used to study the ad-
justed relationship between nadir Hct and end-organ func-
tion and postoperative morbidity and mortality (sensitivity
analyses). The main objective of this ancillary analysis
was to further corroborate the results obtained using the gen-
eralized propensity score method. We considered the fol-
lowing 5 endpoints for the sensitivity analyses: eGFR
(first 3-day minimum), troponin (24-hour mean), ventila-
tion, hospital length of stay, and death. The risk factors asso-
ciated with continuous variables (ie, eGFR, troponin,
duration of ventilation, and hospital length of stay) were
identified using multivariate linear regression (PROC
REG, SAS; SAS Institute, Cary, NC). The risk factors asso-
ciated with the binary variable (receiving ventilation) were
identified using multivariate logistic regression (PROC
REG, SAS; SAS Institute). Survival was assessed nonpara-
metrically using the Kaplan-Meier estimator and parametri-
cally using a multiphase hazard model.E3 The parametric
model was used to resolve a number of phases of instanta-
neous risk of the event (hazard function) and to estimate
the shaping parameters (details can be found at http://my.
clevelandclinic.org/professionals/software/hazard/default.
aspx). Variable selection, with a P value criterion for the re-
tention of variables in the model of .05, used bootstrap bag-
ging (bootstrap aggregation).E4,E5 This was a 4-step process.
First, a patient was randomly selected from the original data
set to begin a new data set. The original data set continued to
be sampled until the new data set was 100% of the size of the
original. Second, risk factors were identified using auto-
mated forward stepwise selection. Third, the results of the
variable selection were stored. These 3 steps were repeated
500 times. Finally, the frequency of the occurrence of vari-
ables related to group membership was ascertained and in-
dicated the reliability of each variable (aggregation step).
All variables with bootstrap reliability of 50% or greater
were retained in the guided analysis (Tables E1 to E6).
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FIGURE E1. Operative trends in hematocrit (Hct) values for the patient
population. CPB, Cardiopulmonary bypass.
TABLE E1. Factors associated with lower eGFR (worse renal
function)
Factor Coefficient ± SD
P
value
Reliability*
(%)
Lower nadir Hct 0.26  0.043 <.0001 93
Older age [(age/50)2, squared
transformation]
3.6  0.28 <.0001 100
Lower preoperative eGFR 1.1  0.034 <.0001 100
(eGFR/75)2, squared
transformation
13  1.2 <.0001 100
Male gender 1.8  0.41 <.0001 92
Cardiogenic shock 12  2.8 <.0001 91
IDDM 2.4  0.69 .0006 88
Hypertension 1.2  0.34 .0005 87
Heart failure 1.4  0.43 .002 85
Stroke 2.1  0.68 .003 81
COPD 1.4  0.52 .006 74
Larger BMI [(40/BMI),
inverse transformation]
10  0.63 <.0001 100
Longer CPB duration 0.031  0.0044 <.0001 99
Lower EF [(50/EF), inverse
transformation]
1.1  0.37 .002 70
eGFR, Estimated glomerular filtration rate; SD, standard deviation; Hct, hematocrit;
IDDM, insulin-dependent diabetes mellitus; COPD, chronic obstructive pulmonary
disease; BMI, body mass index; CPB, cardiopulmonary bypass; EF, ejection fraction.
*Percentage of times the variable appeared in 500 bootstrap models.
TABLE E2. Factors associated with higher troponin release
Factor Coefficient ± SD
P
value
Reliability*
(%)
Lower nadir Hct 0.0082  0.0022 .0002 91
Atrial fibrillation 0.63  0.032 <.0001 100
Race other than white 0.19  0.035 <.0001 99
Heart failure 0.13  0.024 <.0001 99
Preoperative IABP 0.79  0.15 <.0001 98
Lower preoperative eGFRy 0.44  0.031 <.0001 100
Absence of NIDDM 0.056  0.027 .04 68
Smaller BMIz 0.18  0.035 <.0001 100
Longer CPB durationx 0.69  0.029 <.0001 100
Higher bilirubin{ 0.076  0.019 <.0001 92
Fewer previous surgeries 0.12  0.021 <.0001 65
Longer aortic clamp timek 0.14  0.0202 <.0001 100
Other procedures 100
Isolated CABG 0.52  0.026 <.0001
Isolated valve 0.42  0.022 <.0001
Isolated CABGþvalve 0.37  0.031 <.0001
SD, Standard deviation; Hct, hematocrit; IABP, intra-aortic balloon pump; eGFR, es-
timated glomerular filtration rate; NIDDM, non–insulin-dependent diabetes mellitus;
BMI, body mass index; CPB, cardiopulmonary bypass; CABG, coronary artery by-
pass grafting. *Percentage of times the variable appeared in 500 bootstrap models.
yLog (preoperative eGFR), logarithmic transformation. z(40/BMI), inverse transfor-
mation. xLog (time on pumpþ1), logarithmic transformation. {Log (bilirubin), log-
arithmic transformation. kLog (aortic clamp timeþ1), logarithmic transformation.
TABLEE3. Factors associated with higher likelihood of postoperative
ventilator support
Factor Coefficient ± SD
P
value
Reliability*
(%)
Lower nadir Hct 0.12  0.019 <.0001 98
Older agey 0.51  0.091 <.0001 100
Lower EFz 0.602  0.16 .0001 100
Larger BMI 0.071  0.011 <.0001 100
COPD 0.58  0.24 .02 55
Previous cardiac surgery 1.3  0.27 <.0001 71
Longer CPB durationx 1.2  0.13 <.0001 100
Higher preoperative Hct{ 1.6  0.33 <.0001 98
Recent date of surgery 100
Surgery year 2007 vs
2004–2006
0.83  0.14 <.0001
Surgery year 2008 vs
2004–2006
3.3  0.36 <.0001
Surgery year 2009 vs
2004–2006
2.5  0.29 <.0001
Isolated CABG vs other
procedures
0.88  0.23 .0001 75
Isolated valve vs other
procedures
0.69  0.11 <.0001 100
SD, Standard deviation; Hct, hematocrit; EF, ejection fraction; BMI, body mass in-
dex; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass;
CABG, coronary artery bypass grafting. *Percentage of times the variable appeared in
500 bootstrap models. y(Age/50)2, squared transformation. z(EF/50)2, squared trans-
formation. xLog (time on pumpþ1), logarithmic transformation. {(Preoperative Hct/
40)2, squared transformation.
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TABLE E4. Factors associated with increased duration of ventilator
support
Factor Coefficient ± SD
P
value
Reliability*
(%)
Lower nadir Hct 0.013  0.0031 <.0001 95
Older agey 0.17  0.016 <.0001 100
Race other than white 0.102  0.035 .004 77
Lower EFz 0.18  0.036 .0001 99
Larger BMI 0.024  0.0016 <.0001 100
COPD 0.14  0.228 <.0001 99
Previous cardiac surgery 0.13  0.26 <.0001 87
Longer CPB duration 0.0037  0.00025 <.0001 100
Higher preoperative Hctx 0.23  0.053 <.0001 98
Preoperative IABP 1.1  0.15 <.0001 100
Emergency surgery 0.75  0.14 <.0001 96
Heart failure 0.095  0.025 .0001 96
Internal thoracic artery
grafting
0.084  0.023 .0003 88
IDDM 0.14  0.038 .0004 75
History of myocardial
infarction
0.070  0.024 .004 84
Higher NYHA functional
class
0.044  0.012 .0005 82
Cardiogenic shock 0.49  0.15 .001 80
Higher bilirubin{ 0.030  0.0076 .0001 84
Peripheral arterial disease 0.042  0.022 .05 67
Absence of LMT disease
(70% stenosis)
0.094  0.042 .03 62
Stroke 0.088  0.038 .02 60
Atrial fibrillation 0.063  0.032 .05 57
Isolated valve vs other
procedures
0.13  0.022 <.0001 100
Isolated CABGþvalve vs
other procedures
0.068  0.029 .02 61
SD, Standard deviation; Hct, hematocrit; EF, ejection fraction; BMI, body mass in-
dex; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass;
IABP, intra-aortic balloon pump; IDDM, insulin-dependent diabetes mellitus; NYHA,
New York Heart Association; LMT, left main trunk; CABG, coronary artery bypass
grafting. *Percentage of times the variable appeared in 500 bootstrap models.
y(Age/50)2, squared transformation. zLog (EF), logarithmic transformation. x(Preop-
erative Hct/40)2, squared transformation. {(Bilirubin)2, squared transformation.
TABLE E5. Factors associated with increased length of hospital stay
Factor Coefficient ± SD
P
value
Reliability*
(%)
Lower nadir Hct 0.0036  0.0017 .03 96
Older agey 0.053  0.0060 <.0001 100
AF 0.065  0.017 .0001 97
Higher NYHA functional
class
0.059  0.0066 <.0001 100
Heart failure 0.13  0.013 <.0001 100
Stroke 0.15  0.0202 <.0001 100
COPD 0.13  0.013 <.0001 100
Race other than white 0.092  0.018 <.0001 100
Cardiogenic shock 0.85  0.0801 <.0001 100
Larger BMIz 0.16  0.019 <.0001 100
Female gender 0.040  0.012 .002 90
Lower EFx 0.28  0.019 <.0001 100
Lower BUN{ 0.027  0.012 .02 92
Lower preoperative Hctk 0.24  0.057 <.0001 82
History of myocardial
infarction
0.043  0.012 .0005 83
IDDM 0.072  0.021 .0005 80
Previous cardiac surgery 0.057  0.014 <.0001 78
Higher bilirubin 0.048  0.012 <.0001 94
Peripheral arterial disease 0.099  0.012 <.0001 63
Isolated valve vs other
procedures
0.12  0.0104 <.0001 100
Isolated valveþCABG vs
other procedures
0.091  0.016 <.0001 100
Longer CPB duration 0.0013  0.00013 <.0001 99
SD, Standard deviation; Hct, hematocrit; AF, atrial fibrillation; NYHA, New York
Heart Association; COPD, chronic obstructive pulmonary disease; BMI, body mass
index; EF, ejection fraction; BUN, blood urea nitrogen; IDDM, insulin-dependent di-
abetes mellitus; CABG, coronary artery bypass grafting; CPB, cardiopulmonary by-
pass. *Percentage of times the variable appeared in 500 bootstrap models. yExp (age/
50), exponential transformation. z(BMI/40)2, squared transformation. xLog (EF), log-
arithmic transformation. {(20/BUN), inverse transformation. k(40/Preoperative Hct),
inverse transformation.
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TABLEE7. Summaryof risk-adjusted association of nadir hematocrit
and end-organ dysfunction: composite for Tables E1–E6
Outcome Effect (P value)
Interpretation
(lower nadir Hct
associated with)
eGFR (first 3-d minimum) 0.26 (<.0001) Lower eGFR
Troponin (24-h mean)* 0.0082 (.0002) Higher troponin
Ventilation
Postoperative ventilation 0.12 (<.0001) Higher likelihood
Ventilation duration* 0.013 (<.0001) Longer duration
Hospital length of stay* 0.0036 (.03) Longer duration
Death
Early 0.054 (.15) Increased risk
Late 0.048 (.005) Increased risk
Hct, Hematocrit; eGFR, estimated glomerular filtration rate. *Logarithmic transfor-
mation was used as the response variable.
TABLE E6. Factors associated with increased likelihood of death
Factor Coefficient ± SD
P
value
Reliability*
(%)
Early decreasing phase
Lower nadir Hct 0.054  0.038 .15 39
Older agey 0.51  0.14 .0002 94
Higher NYHA functional
class
0.41  0.16 .01 62
AF 0.63  0.25 .01 75
Heart failure 1.3  0.24 <.0001 99
IDDM 0.74  0.30 .01 53
Stroke 0.71  0.30 .02 61
Lower preoperative Hctz 1.9  0.86 .03 63
Lower BUNx 0.51  0.13 .0001 71
Lower preoperative eGFR{ 0.16  0.079 .04 59
Longer aortic clamp timek 0.21  0.079 .008 66
Late increasing phase
Lower nadir Hct 0.048  0.017 .005 67
Older age# 0.56  0.089 <.0001 100
Stroke 0.45  0.20 .02 100
History of MI 0.38  0.15 .01 70
Lower EF** 0.51  0.166 .002 76
COPD 0.59  0.16 .0002 78
Smoking 0.36  0.15 .02 76
Peripheral arterial disease 0.64  0.16 <.0001 70
Higher BUN 0.044  0.0059 <.0001 93
Higher bilirubinyy 0.077  0.030 .01 60
SD, Standard deviation; Hct, hematocrit; NYHA, New York Heart Association; AF,
atrial fibrillation; IDDM, insulin-dependent diabetes mellitus; BUN, blood urea nitro-
gen; eGFR, estimated glomerular filtration rate;MI, myocardial infarction; EF, ejec-
tion fraction; COPD, chronic obstructive pulmonary disease. *Percentage of times
the variable appeared in 500 bootstrap models. yExp (age/50), exponential transfor-
mation. z(40/preoperative Hct), inverse transformation. x(40/BUN), inverse transfor-
mation. {(75/preoperative eGFR), inverse transformation. k(aortic clamp time/70)2,
squared transformation. #Exp (age/50), exponential transformation. **(EF/50)2,
squared transformation. yy(Bilirubin)2, squared transformation.
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